From: Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients
Polymorphism
Genotype
(CCyR)*
(Non-CyR)**
P
C421A
CA
6 (54.5%)
5 (45.5%)
0.737
CC
19 (45.2%)
23 (54.8%)
G34A
AG
18 (48.6%)
19 (51.4%)
0.774
GG
7 (43.8%)
9 (56.2%)